Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder

NCT06261060 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

6

Enrollment

OTHER

Sponsor class

Conditions

Familial Platelet Disorder
Hematopoietic

Interventions

DRUG: Sirolimus

Sponsor

M.D. Anderson Cancer Center